$250B Bitcoin Reserve? Pompliano’s Vision to Make US the King of Crypto 
Nvidia Drives S&P 500 Gains as AI Enthusiasm Climbs Amid Rising Russia-Ukraine Nuclear Tensions 
Understanding The Growing Trend Of Unsecured Personal Loans 
AMD's Accounting Shake-Up: 'Smith's Sudden Exit Sparks Speculation' 
Ram’s First Electric Pickup Delayed Again: 1500 REV Aims to Redefine EV Trucks in 2025 
Wall Street in Shock! US-Russia Fright Fades as All Eyes Turn to Nvidia Earnings Bombshell 
Huawei’s AI Chip Struggles: 7nm Tech Falls Generations Behind NVIDIA Due to US Sanctions, TSMC Blockade 
Trump Meets Coinbase CEO Brian Armstrong for Key Appointment Talks — WSJ 
Superlobbyist Nick Muzin on Intense Political Campaign Management 
Nvidia Faces Market Scrutiny Amid AI Chip Woes as Wall Street Holds Its Breath for Earnings 
Trump to Slash Biden's EV Push: Fuel-Efficiency Standards and Tax Credits on the Chopping Block 
Super Micro Computer Fights Back: 'Nasdaq Delisting Will Not Happen!' Shares Soar Amid Bold Comeback 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
